Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Single Center, Randomized, Pharmacoscintigraphic Study to Evaluate the Relative Bioavailability of E7386 Following Oral Administration of Targeted Release Tablets Compared to an E7386 Immediate Release Tablet in Healthy Adult Subjects

Next Previous
X
Search
Trial Profile

An Open-Label, Single Center, Randomized, Pharmacoscintigraphic Study to Evaluate the Relative Bioavailability of E7386 Following Oral Administration of Targeted Release Tablets Compared to an E7386 Immediate Release Tablet in Healthy Adult Subjects

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 28 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eribulin (Primary) ; Eribulin
  • Indications Bladder cancer; Breast cancer; Colorectal cancer; Ewing's sarcoma; Glioblastoma; Haemangioendothelioma; Haemangiosarcoma; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Soft tissue sarcoma; Solid tumours; Urogenital cancer
  • Focus Pharmacokinetics
  • Sponsors Eisai Co Ltd

    • Most Recent Events

    • 22 Nov 2023 Status changed from suspended to withdrawn prior to enrolment.
    • 08 Nov 2022 Planned End Date changed from 30 Jun 2023 to 20 Nov 2023.
    • 08 Nov 2022 Planned primary completion date changed from 30 Jun 2023 to 20 Nov 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top